scholarly journals Colonic Diverticulosis and Non-Alcoholic Fatty Liver Disease: Is There a Connection?

Medicina ◽  
2021 ◽  
Vol 58 (1) ◽  
pp. 38
Author(s):  
Ivana Pantic ◽  
Sofija Lugonja ◽  
Nina Rajovic ◽  
Igor Dumic ◽  
Tamara Milovanovic
Keyword(s):  
Blood Pressure ◽  
Liver Disease ◽  
Fatty Liver ◽  
Total Cholesterol ◽  
Hepatic Steatosis ◽  
Fatty Liver Disease ◽  
Colonic Surgery ◽  
Colonic Diverticulosis ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background and Objectives: The development and severity of colonic diverticulosis and non-alcoholic fatty liver disease (NAFLD) has been associated with several components of metabolic syndrome (MetS). Therefore, this study aimed to evaluate a possible connection between NAFLD, colonic diverticulosis, and MetS. Materials and Methods: This retrospective study included patients diagnosed with diverticulosis between January 2017 and December 2019. Data regarding the patient demographics, Diverticular Inflammation and Complication Assessment (DICA) score and category, disease localization, hepatic steatosis, blood pressure, comprehensive metabolic panel, need for colonic surgery, and co-morbidities were collected from medical records. Results: A total of 407 patients with a median age of 68 years (range, 34–89 years) were included (male: 53.81%). The majority was diagnosed with left-sided diverticulosis (n = 367, 90.17%) and an uncomplicated disease course (DICA category 1, n = 347, 85.3%). Concomitant hepatic steatosis was detected in 47.42% (n = 193) of patients. The systolic blood pressure, triglycerides, total cholesterol, C-reactive protein (CRP), and fasting glucose were higher in the NAFLD group (p < 0.001, p < 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively). A higher prevalence of hypertension (HTA), type 2 diabetes mellitus (T2DM), and hypothyroidism was noted in the same group of patients (p < 0.001, p < 0.001, and p = 0.008, respectively). High-density lipoprotein cholesterol was lower in patients with more severe forms of diverticulosis (DICA category 2 and 3), while CRP levels were significantly higher (p = 0.006 and p = 0.015, respectively). HTA and NAFLD were more common in patients with more severe forms of colonic diverticulosis (p = 0.016 and p = 0.025, respectively). Using a multivariate logistic regression, the DICA score, CRP, total cholesterol, HTA, and hypothyroidism were identified as discriminating factors for the presence of hepatic steatosis. Conclusion: Components of metabolic dysregulation were prominent in patients diagnosed with colonic diverticulosis and concomitant hepatic steatosis. HTA, T2DM, and hypothyroidism were more frequently observed in this group. Hepatic steatosis was more commonly detected in more severe forms of colonic diverticulosis.

scholarly journals Association Between Hepatic Steatosis and Metabolic Syndrome in Patients With Non-alcoholic Fatty Liver Disease

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 858-858
Author(s):  
Victoria Quadros Pereira ◽  
Carine Panke ◽  
Leticia Eifler ◽  
Cristiane Tovo ◽  
Thaís Moreira
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Liver Disease ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Fatty Liver Disease ◽  
Serum Triglycerides ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Abstract Objectives Evaluate the association between the degree of hepatic steatosis and the development of metabolic syndrome in outpatients care. Methods Prospective cross-sectional study with outpatients care at the Gastroenterology Service of a hospital in southern Brazil. The study was approved by the Ethics Committee with protocol 57,328,416.8.0000.5335. Patients aged over 18 years and with non-alcoholic fatty liver disease were included. Patients were excluded from hepatitis B and C, with significant alcohol consumption and hepatocellular carcinoma. Data collection occurred during nutritional consultations, where we collected data of age, gender, lifestyle, diagnosis of comorbidities and biochemical tests. The result of liver biopsy was evaluated for the degree of hepatic steatosis. Anthropometric parameters were assessed for the diagnosis of metabolic syndrome, in addition to electrical bioimpedance for body composition. Data were presented as mean, median, standard deviation, interquartile range and percentages according to distribution. Student T, ANOVA and Pearson correlation tests were applied. The significance level was 5%. Results We evaluated 71 patients with mean age 59.08 ± 8.92 years, 67.6% (n = 48) women, 60.6% (n = 43) sedentary, 52.2% (n = 37) no smoking and mean body mass index of 32.91 ± 5.27 kg/m2. Systemic arterial hypertension were diagnosed in 80.3% (n = 57), 73.2% (n = 52) were diabetic, 66.2% (n = 47) were dyslipidemic and 28.2% (n = 20) of patients with metabolic syndrome. As liver biopsy, 25.4% (n = 18) mild steatosis, 23.9% (n = 17) moderate and 26.8% (n = 19) intense. In the comparison between the levels of hepatic steatosis and the variables, it was observed that patients with severe steatosis had metabolic syndrome (p = 0.041). Patients with metabolic syndrome have higher fat mass (p = 0.044), diastolic blood pressure (p = 0.019) and higher levels of serum triglycerides (p = 0.043). Severe hepatic steatosis correlated with the diagnosis of metabolic syndrome (r = 0.319; p = 0.019). Conclusions Severe hepatic steatosis is related to the diagnosis of metabolic syndrome.Patients with metabolic syndrome had a higher amount of fat mass, increased diastolic blood pressure and serum triglycerides. Funding Sources This study was not funded.

scholarly journals Arazyme Suppresses Hepatic Steatosis and Steatohepatitis in Diet-Induced Non-Alcoholic Fatty Liver Disease-Like Mouse Model

2019 ◽  
Vol 20 (9) ◽  
pp. 2325 ◽  
Author(s):  
Hua Li ◽  
Wonbeak Yoo ◽  
Hye-Mi Park ◽  
Soo-Youn Lim ◽  
Dong-Ha Shin ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Fatty Liver Disease ◽  
Fatty Acid Synthase ◽  
Regulatory Element ◽  
Diet Group ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Arazyme, a metalloprotease from the spider Nephila clavata, exerts hepatoprotective activity in CCL4-induced acute hepatic injury. This study investigated the hepatoprotective effects in high-fat diet (HFD)-induced non-alcoholic fatty liver disease-like C57BL/6J mice. The mice were randomly divided into four groups (n = 10/group): the normal diet group, the HFD group, the arazyme group (HFD with 0.025% arazyme), and the milk thistle (MT) group (HFD with 0.1% MT). Dietary supplementation of arazyme for 13 weeks significantly lowered plasma triglyceride (TG) and non-esterified fatty acid levels. Suppression of HFD-induced hepatic steatosis in the arazyme group was caused by the reduced hepatic TG and total cholesterol (TC) contents. Arazyme supplementation decreased hepatic lipogenesis-related gene expression, sterol regulatory element-binding transcription protein 1 (Srebf1), fatty acid synthase (Fas), acetyl-CoA carboxylase 1 (Acc1), stearoyl-CoA desaturase-1 (Scd1), Scd2, glycerol-3-phosphate acyltransferase (Gpam), diacylglycerol O-acyltransferase 1 (Dgat1), and Dgat2. Arazyme directly reduced palmitic acid (PA)-induced TG accumulation in HepG2 cells. Arazyme suppressed macrophage infiltration and tumor necrosis factor α (Tnfa), interleukin-1β (Il1b), and chemokine-ligand-2 (Ccl2) expression in the liver, and inhibited secretion of TNFα and expression of inflammatory mediators, Tnfa, Il1b, Ccl2, Ccl3, Ccl4, and Ccl5, in PA-induced RAW264.7 cells. Arazyme effectively protected hepatic steatosis and steatohepatitis by inhibiting SREBP-1-mediated lipid accumulation and macrophage-mediated inflammation.

Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis

2019 ◽  
Vol 29 (7) ◽  
pp. 3564-3573 ◽  
Author(s):  
Jiulian Gu ◽  
Shousheng Liu ◽  
Shuixian Du ◽  
Qing Zhang ◽  
Jianhan Xiao ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document